USFDA granted approval to Aurobindo Pharma for Flucytosine Capsules

Aurobindo Pharma received its final approval from the US Food & Drug Administration (USFDA) to manufacture and market Flucytosine Capsules, 250 mg and 500 mg.

Flucytosine Capsules are used for the treatment of serious infections caused by susceptible strains of Candida and Cryptococcus. The Capsules are a generic version of Bausch Health’s Ancobon Capsules and the capsules will be launched in June 2020.

A total of 429 ANDA approvals has been granted to Aurobindo (401 Final approvals including 23 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

  • Related Posts

    GSK Pharma forays into gynaecological cancer treatment in India

    GlaxoSmithKline Pharmaceuticals Ltd. stock zoomed as much as 2% on Monday, August 25. This movement in shares came after the company announced its entry into the oncology segment in India…

    Hyderabad rising in biotech, pharma, medtech innovation: Revanth Reddy

    Hyderabad:  Chief Minister A Revanth Reddy said Hyderabad was India’s emerging hub of biotech, pharma, and medical technology innovation, with the ambition to become a $1 trillion economy by 2034.…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    GSK Pharma forays into gynaecological cancer treatment in India

    GSK Pharma forays into gynaecological cancer treatment in India

    Hyderabad rising in biotech, pharma, medtech innovation: Revanth Reddy

    Hyderabad rising in biotech, pharma, medtech innovation: Revanth Reddy

    DCGI issued alert regarding theft of Novo Nordisk injectables

    DCGI issued alert regarding theft of Novo Nordisk injectables

    Two firms fined for selling spurious cosmetic products

    Two firms fined for selling spurious cosmetic products